San Antonio Researchers Uncover New Pathways in Alzheimer’s Treatment

A significant breakthrough by scientists at the University of Texas at San Antonio could pave the way for innovative treatments for Alzheimer’s disease. Researchers have revealed that changes in lipid levels in the brain, specifically a lipid known as Bis(monoacylglycero)phosphate (BMP), may play a crucial role in the progression of the disease. This discovery challenges the longstanding focus on amyloid plaques and tau proteins, which have dominated Alzheimer’s research thus far.

According to Juan Pablo Palavicini, an assistant professor in the Department of Cellular and Integrative Physiology and a researcher at the Sam and Ann Barshop Institute for Longevity and Aging Studies, lipids make up more than half of the brain’s dry weight. Despite their importance, many researchers have overlooked their potential influence on Alzheimer’s disease. Palavicini and his colleague Xianlin Han led a study in collaboration with the University of California at Irvine, which found that microglia, the brain’s immune cells, can cause lipid abnormalities associated with the disease.

Palavicini described microglia as the brain’s janitorial staff, tasked with clearing away debris generated during normal brain function. “When a brain is functioning well, microglia work like janitors at a school, cleaning up the mess created by students,” he explained. However, as the brain ages and in the context of Alzheimer’s, these cells become overwhelmed by accumulating debris, leading to their eventual exhaustion.

In their research, published in October 2023 in the journal Nature Communications, the team deactivated microglia in one group of mice and bred another group that lacked these cells entirely. They then compared lipid changes in these mice with post-mortem brain samples from individuals with and without Alzheimer’s disease. The absence of microglia resulted in a notable decrease in BMP levels, indicating that the increase in this lipid during Alzheimer’s is driven by microglia.

“This was completely unexpected,” Palavicini stated, highlighting the surprise of discovering that microglia directly influence BMP levels in response to lipid debris and amyloid plaques. He further noted that even if current treatments manage to clear amyloid plaques, the damage already inflicted by these proteins complicates recovery due to the accumulation of lipid debris.

In healthy brains, myelin—an insulating layer around nerve cells—facilitates effective communication between neurons. As Alzheimer’s progresses, myelin degrades, leading to impaired neuron function. Palavicini pointed out that as microglia become overwhelmed, the necessary repair mechanisms for myelin are inhibited, exacerbating cognitive decline.

Understanding this relationship between microglia and lipid metabolism could lead to new therapeutic approaches aimed at enhancing the brain’s ability to repair itself. “We need to find ways to improve microglial function so that the brain can remyelinate and recover from lipid loss,” Palavicini emphasized. “Therapies that support microglial function may slow cognitive decline in Alzheimer’s patients.”

This research not only provides a fresh perspective on Alzheimer’s treatment but could also shift the focus of future studies towards lipid metabolism and its implications for brain health. The findings underscore the importance of a multifaceted approach to understanding and treating complex neurodegenerative diseases. As research continues, the hope remains that these insights will lead to effective interventions that could significantly alter the course of Alzheimer’s disease.